Genocea Biosciences, Inc. (GNCAQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Jan 21, 2025, 9:30 AM EST
Market Cap 59.00
Revenue (ttm) 1.91M
Net Income (ttm) -37.19M
Shares Out 58.78M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 4,539
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta 27.45
RSI 46.31
Earnings Date n/a

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 74
Stock Exchange OTCMKTS
Ticker Symbol GNCAQ
Full Company Profile

Financial Performance

In 2021, Genocea Biosciences's revenue was $1.64 million, an increase of 20.75% compared to the previous year's $1.36 million. Losses were -$33.20 million, -24.06% less than in 2020.

Financial Statements

News

There is no news available yet.